Gennex Laboratories share news and announcements

BSE: 531739Pharmaceuticals & BiotechnologySmall Cap

₹8.70₹0.15 (1.69%)

Share price at the BSE close on 23 Oct 2026. Previous close ₹8.85.

52-week range of traded prices to 23 Oct 2026

₹7.05Low, 30 Mar 2026₹17.25High, 28 Oct 2025

Market cap: ₹211 Cr2,248th largest listed
P/E: 11.5
P/B: 0.9
Dividend yield: Nonein the last 12 months
ROE: 9.0%
ROCE: 7.0%
Debt to equity: 0.15
Volume, BSE: 2,30,459

Gennex Laboratories share news and announcements

553 announcements, routine notices left out, newest first. Page 5 of 12.

Sep 2022
Aug 2022
- 30 Aug · Board meeting
  Meeting on 6 Sep 2022: annual general meeting
- 30 Aug · Board meeting
  GENNEX LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/09/2022 ,inter alia, to consider and approve With reference to the .... (opens in a new tab)
- 26 Aug · Announcement under Regulation 30 (LODR)-Allotment
  With reference to captioned subject and in furtherance of Rights Issue of the Company, this is to inform that in terms of the Letter of Offer dated July 16, 2022 and in accordance with .... (opens in a new tab)
- 12 Aug · Results
  In just concluded Meeting of the Board Directors of the Company, the board has considered and approved: 1. Unaudited (Standalone and Consolidated) Financial Statements for the .... (opens in a new tab)
- 12 Aug · Board meeting
  In just concluded Meeting of the Board Directors of the Company, the board has considered and approved: 1. Unaudited (Standalone and Consolidated) Financial Statements for the .... (opens in a new tab)
- 11 Aug · Disclosure
  Exchange has received the Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations, 2011 on August .... (opens in a new tab)
- 11 Aug · Disclosure
  Exchange has received the Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations, 2011 on August .... (opens in a new tab)
- 11 Aug · Disclosure
  Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on August 11, 2022 for VAB Ventures Ltd (opens in a new tab)
- 11 Aug · Disclosure
  Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on August 11, 2022 for VAB Ventures Ltd (opens in a new tab)
- 1 Aug · Board meeting
  Meeting on 12 Aug 2022: quarterly results
- 1 Aug · Board meeting
  GENNEX LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2022 ,inter alia, to consider and approve With reference to the .... (opens in a new tab)
Jul 2022
- 27 Jul · Business
  We are pleased to inform you that the Company has received new 2 Licences to manufacture drugs for purposes of examination, test or analysis from the Drug Control Administration, Government .... (opens in a new tab)
- 26 Jul · Disclosure
  Exchange has received the Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations, 2011 on July .... (opens in a new tab)
- 26 Jul · Disclosure
  Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on July 26, 2022 for VAB Ventures Ltd (opens in a new tab)
- 26 Jul · Disclosure
  Exchange has received the Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations, 2011 on July .... (opens in a new tab)
- 26 Jul · Disclosure
  Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on July 26, 2022 for VAB Ventures Ltd (opens in a new tab)
- 16 Jul · Statement Of Investor Complaints For The Quarter Ended June 2022
  No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0 0 0 0
- 16 Jul · Announcement under Regulation 30 (LODR)-Meeting Updates
  Pursuant to the submitted Board Meeting outcome, held on July 16, 2022, the Company adopted the Letter of Offer, Abridge Letter of Offer and ISIN for Rights Entitlement. (opens in a new tab)
- 16 Jul · Corporate action
  We inform you that the Rights Issue Committee constituted by the Board of Directors of the Company has, at its meeting held today, fixed Friday, July 22, 2022 as the 'Record Date' for the .... (opens in a new tab)
- 16 Jul · Board meeting
  With reference to the Captioned subject matter and pursuant Reg.30 of SEBI(LODR) Regulations, 2015, This is to inform you that the Board of Directors in their meeting held Friday, June .... (opens in a new tab)
- 13 Jul · Board meeting
  Meeting on 16 Jul 2022: rights issue and rights issue of equity shares
- 13 Jul · Board meeting
  GENNEX LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 16/07/2022 ,inter alia, to consider and approve 1. To consider and approve .... (opens in a new tab)
- 1 Jul · Disclosure
  Exchange has received updates on Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on July 01, 2022 for Vab Ventures Ltd (opens in a new tab)
Jun 2022
- 24 Jun · Board meeting
  Outcome of the Board Meeting held on June 24, 2022. (opens in a new tab)
- 21 Jun · Board meeting
  Meeting on 24 Jun 2022: rights issue of equity shares
- 21 Jun · Board meeting
  GENNEX LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 24/06/2022 ,inter alia, to consider and approve With reference to the .... (opens in a new tab)
- 14 Jun · Disclosure Pursuant To Regulation 23(9) Of The SEBI (LODR) Regulations, 2015 For The Half Year Ended March 31, 2022
  Pursuant to the provision of Regulation.23(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby submit the attached note on Related party Transaction .... (opens in a new tab)
May 2022
- 30 May · Results
  In just concluded Meeting of Board of Directors, the Board Approved and considered the following items: 1. Audited Standalone & Consolidated Financial results for the quarter ended .... (opens in a new tab)
- 30 May · Board meeting
  In just concluded Meeting of Board of Directors, the Board Approved and considered the following items: 1. Audited Standalone & Consolidated Financial results for the quarter ended .... (opens in a new tab)
- 23 May · Board meeting
  Meeting on 30 May 2022: audited results and quarterly results
- 23 May · Board meeting
  GENNEX LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2022 ,inter alia, to consider and approve the Audited (Standalone .... (opens in a new tab)
Apr 2022
- 26 Apr · Compliance Certificate Under Regulation 40(9) & 40(10) Of The SEBI (Listing Obligation And Disclosure Requirements) Regulations, 2015 Of Gennex Laboratories Limited For The Year Ended March 31, 2022
  With reference to the above captioned subject matter, Pursuant to Regulation 40(9) & (10) of the SEBI (LODR) Regulations, 2015 enclosed please find the letter dated April 25, 2022, received .... (opens in a new tab)
- 25 Apr · Compliance Certificate Under Regulation 7(2) & 7(3) Of The SEBI (LODR) Regulations, 2015 Of Gennex Laboratories Limited For The Year Ended March 31, 2022
  With reference to the above captioned subject matter, we are hereby enclosing the Compliance certificate Pursuant to Regulation 7(2) & 7(3) of the SEBI (LODR) Regulations 2015 for the year .... (opens in a new tab)
- 20 Apr · Statement Of Investor Complaints For The Quarter Ended March 2022
  No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0 0 0 0
- 6 Apr · Board meeting
  Board of Directors at their meeting held today, approved the offer and issuance of fully paid-up equity shares of the Company (the 'Equity Shares') for an amount not exceeding Rs. 40 .... (opens in a new tab)
Mar 2022
- 28 Mar · Board meeting
  Meeting on 6 Apr 2022: rights issue
- 28 Mar · Board meeting
  GENNEX LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/04/2022 ,inter alia, to consider and approve With reference to the .... (opens in a new tab)
- 15 Mar · Disclosure
  Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on March 15, 2022 for VAB Ventures Ltd (opens in a new tab)
- 3 Mar · Disclosure
  Exchange has received revised Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on March 03, 2022 for VAB Ventures Ltd (opens in a new tab)